Project Grant R01DK148440
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $822K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Cincinnati Children's Hospital Medical Center $714,898 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate regulatory CD4+ T cell dynamics in metabolic dysfunction-associated steatotic liver disease (MASLD). The research examines how the liver microenvironment during MASLD progression shapes the characteristics and functions of hepatic regulatory T...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $814,500 to the University of Pittsburgh on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research dissecting functional decompensation of end-stage liver disease and investigating the mechanism and impact of transcription factors on long-term functional reprogramming. The research examines how the transcription factor HNF4A—which controls...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $550,070 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research elucidating ATP8B1 deficiency using patient-derived induced pluripotent stem cell (iPSC) models. The project addresses progressive familial intrahepatic cholestasis (PFIC) caused by ATP8B1 mutations, a rare inherited liver disease that impairs bile...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $682,894 to St. Jude Children's Research Hospital Inc. on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to elucidate the role of LACTB2 in liver metabolic development. The research identifies critical metabolic regulators and pathways required for liver maturation during...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Cincinnati Children's Hospital Medical Center $851,275 on February 15, 2026, to investigate mechanisms regulating hepatocyte plasticity and competency for reprogramming into cholangiocytes as a potential therapeutic approach for intrahepatic bile duct paucity. The research addresses the scientific barrier that hepatocytes in cholestatic stress can reprogram to form functional intrahepatic bile duct networks, but key...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $154,332 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of kynurenine-aryl hydrocarbon receptor signaling in cholestatic liver injury. The research examines how the kynurenine pathway and aryl hydrocarbon receptor activation regulate reactive oxygen species accumulation,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Cincinnati Children's Hospital Medical Center $1,624,162 on May 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to explore the link between extracellular vesicle-associated inflammation in obesity and sepsis outcomes. The funded research defines upstream regulatory pathways that confer pro-inflammatory properties to liver-derived small extracellular vesicles...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $100,228 on December 8, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD). The research develops and employs a novel in vivo mouse model enabling selective induction of senescence in hepatocytes to examine the effects of...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Medical College of Wisconsin, Inc. $406,985 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms regulating FOXA1 and FOXA2 transcription factors during human liver development. The research addresses how FOXA1 and FOXA2 pioneer transcription factors regulate chromatin opening and gene activation required for hepatic...